Oxycodone Statistics

Oxycodone by the numbers: the 866% sales surge, the prescribing peak and decline, who is affected, overdose deaths and trends, the pills-to-heroin-to-fentanyl pipeline, the treatment gap, and where to get help.

Jessica Miller is the Content Manager of Addiction HelpWritten by
Kent S. Hoffman, D.O. is a founder of Addiction HelpMedically reviewed by Kent S. Hoffman, D.O.
Last updated

Battling addiction & ready for help?

Find Treatment Now

What the Oxycodone Numbers Actually Say

If you are looking up oxycodone statistics, you are probably trying to size up a worry: how big is this, how did it get this bad, and is the person you love (or you) part of a number that ends badly.

Here is the plain version. Oxycodone helped set off the deadliest drug crisis in American history. Sold as OxyContin, Percocet, and Roxicodone, it saw retail sales jump 866% in a single decade, and that wave of pills pushed a generation toward heroin and then fentanyl[1][2].

That is the hard part. The hopeful part is just as real: this is a treatable medical condition, the medications that work are better than ever, and the same data that counts the deaths also counts the people getting out.

An opioid overdose can be reversed, if you act fast. Naloxone (Narcan) buys the minutes that save a life.
Call or text 988 any time if you or someone you love is in crisis.

What to do:

  • Carry naloxone (Narcan). It reverses an opioid overdose within minutes and is sold over the counter. If someone has slow or stopped breathing, blue or gray lips, or you cannot wake them, give it and call 911. Find treatment and someone who can help.
  • Get into treatment. Methadone and buprenorphine (Suboxone) ease withdrawal and cut the risk of dying. This is the easier way out, not the harder one.
  • Never use alone. Most overdose deaths happen with no one there to call for help or give naloxone.

Find treatment today →

AddictionHelp.com Fast Facts
  • Sales explosion: oxycodone retail sales rose 866% between 1997 and 2007, the wave of pills that set off the crisis[1]
  • Recent deaths: nearly 80,000 Americans died of opioid-related causes in 2023[3]
  • The treatment gap: only 25.1% of people with opioid use disorder got the medications that work, the most fixable number anywhere in oxycodone’s story[4]

The Numbers that Defined the Oxycodone Era

A handful of figures tell most of the story.

  • +866% — oxycodone retail sales, 1997 to 2007, a surge no medical need can explain[1]
  • +280% — oxycodone distributed per person in the United States, 2000 to 2010[5]
  • about -54% — the decline from that peak through 2021, as prescribing tightened[5]
  • +806% — opioid-related deaths over roughly the same stretch, 2000 to 2021[5]
  • nearly 80,000 — Americans dying of opioid-related causes each year by 2023[3]

The geography was lopsided. At the 2010 peak there was a 15-fold difference in oxycodone distribution between the highest and lowest states, with Florida, Delaware, and Tennessee carrying consistently elevated levels[5][3]. Where the pills flowed heaviest, the harm followed.

What this means: the rise was not a natural response to unmet pain. It tracked the marketing of a single drug, and when prescribing finally fell, the dying did not stop, because by then the crisis had already moved on to other opioids.

Oxycodone Statistics at a Glance

Statistic Figure Source
Retail sales increase, 1997 to 2007 +866% [1]
Oxycodone per person, 2000 to 2010 +280% [5]
Decline from peak through 2021 about -54% [5]
State-to-state distribution gap at 2010 peak 15-fold [5]
US adults with opioid use disorder, 2022 9.37 million (3.7%) [4]
Opioid-related deaths, 2000 to 2021 +806% [5]
US opioid-related deaths, 2023 nearly 80,000 [3]
US opioid-overdose deaths, 2024 53,774 [4]
Receiving methadone or buprenorphine, 2022 only 25.1% [4]

Who Oxycodone Addiction Affects

What 'opioid use disorder' meansIt is the clinical name for opioid addiction: a diagnosable medical condition, not a label for weak people. When you see it counted here, picture neighbors and coworkers who meet a doctor’s checklist, not a separate kind of person.

Opioid use disorder is common, not rare or far-off. In 2022, an estimated 9.37 million US adults — about 3.7% — met criteria for opioid use disorder, and worldwide roughly 27 million people are affected[4][6]. These are coworkers, parents, and neighbors, not a separate kind of person.

Risk is also uneven, and a lot of it is biology rather than willpower. In large behavioral studies, the strongest initial pain relief predicted the strongest addiction-like behavior, with that early response accounting for roughly 40% of the variation in how compulsively the drug was used[7]. The person who feels the most relief may carry more risk, through no fault of their own.

A few more numbers fill in the picture:

  • 8 to 12% of people who misuse prescription opioids go on to develop opioid use disorder[8]
  • 59.5% of people with opioid use disorder have another active substance use disorder, most often cocaine, alcohol, or cannabis[9]
  • 36.1% live with current depression, and many also carry anxiety, PTSD, or ADHD[10]
  • A 3-fold increase in total oxycodone exposure can come from combining it with CBD products, raising overdose risk even at a prescribed dose[11]

What this means: addiction is not a character flaw, and it rarely travels alone. The same biology that makes some people more vulnerable also responds to treatment, which is exactly why the numbers that follow matter.

Did you know?

Oxycodone is broken down in the body into oxymorphone, a more potent opioid, which is part of why formal assessments rate it high on “liking,” “wanting,” and abuse liability[1][12]. Feeling a powerful pull from a legitimate prescription is a known risk signal, not a moral failing, and it is treatable.

Overdose Deaths and the Trend over Time

What 'involved in' a death meansOverdose counts say a drug was “involved in” a death, which is not the same as saying it acted alone. Most fatal overdoses mix several drugs, so the same death can be counted under more than one substance.

The death curve is the hardest data here, and the most important to read honestly. Opioid-related deaths rose 806% from 2000 to 2021, and by 2023 nearly 80,000 Americans were dying of opioid-related causes each year[5][3]. In 2024, opioid use disorder and overdose were tied to 53,774 deaths in the United States, a toll that has roughly doubled over twenty years[4].

Oxycodone’s name still shows up in that count. It has ranked among the drugs most frequently involved in US overdose deaths from 2017 to 2023, alongside fentanyl and heroin[13]. Much of today’s danger comes from counterfeit pills pressed to look exactly like pharmaceutical oxycodone but containing illicit fentanyl, which kill people who believe they are taking a known dose of a known drug[14].

What this means: the deaths did not stop when prescribing fell. The risk shifted into a deadlier supply, which is why no one using illicit pills can count on what is actually in them, and why naloxone and treatment are the things that move this number.

What the OxyContin Reformulation Actually Changed

In 2010, OxyContin was reformulated to resist crushing and dissolving, the trick people used to defeat its slow release and get a fast high. The numbers show a clear, narrow win that came with a heavy cost. The wins are real, and so is the displacement that came with them.

What changed after the 2010 reformulation Figure Source
Doctor-shopping for brand ER oxycodone, overall -50% [15]
Doctor-shopping among young adults -73% [15]
Doctor-shopping in the highest-risk group -90% [15]
Past-month OxyContin abuse, by mid-2012 45.1% → 26.0% [16]
Abuse of the reformulated ER product (poison-center data) -36% [2]
Abuse of other single-entity oxycodone +20% [2]
Heroin abuse exposures, same period +42% [2]
NYC oxycodone 80 mg patients who switched to other opioids 40% switched [17]
NYC oxycodone 80 mg patients who stopped opioids entirely only 14% [17]
Experienced users who defeated the abuse-deterrent design about 34% [16]

The top of that table is the win: misuse of the targeted product dropped sharply, and doctor-shopping fell by as much as 90% in the highest-risk group[15]. The bottom is the cost: the demand did not disappear, it moved, and heroin exposures rose 42% while about a third of experienced users defeated the new design anyway[2][16].

What this means: making one pill harder to abuse moved people toward heroin rather than toward treatment. Cutting supply alone does not fix addiction[16]. The way out has to include treatment, not just a tamper-resistant tablet.

The Pills-to-Heroin-to-Fentanyl Pipeline, in Data

The oxycodone story does not stay with oxycodone, and the data shows why. As reformulation and tighter prescribing squeezed the pill supply, displaced demand flowed into heroin, with that 42% jump in heroin exposures arriving right alongside the 2010 reformulation[2]. Heroin markets then expanded to meet the demand, and suppliers began cutting and replacing heroin with illicit fentanyl, a synthetic opioid many times more potent and far cheaper to make.

Today the danger has circled back to oxycodone’s own name. Counterfeit pills pressed to look like pharmaceutical oxycodone, but carrying illicit fentanyl, are a documented driver of overdose deaths[14], and oxycodone remains among the drugs most often involved in fatal overdoses[13].

What this means: a person can start with a real prescription, develop dependence, lose access when the rules change, move to heroin, and then meet fentanyl, each step more lethal than the last. If you or someone you love is anywhere on that path, the safest move is not to manage it alone. Medical detox and the medications that follow are built for exactly this. Know the full risks of oxycodone and how dependence takes hold, and what oxycodone withdrawal really looks like.

The Treatment Gap, and the Statistic that Matters Most

The treatment gap is the fixable partThe treatment gap is the distance between the people who could be helped and the people who actually get help. Of every number here, this is the one a phone call can change.

It is easy to drown in the loss in these numbers, so end with the ones that point the other way. Opioid use disorder is treatable, yet in 2022 only 25.1% of people who had it received methadone or buprenorphine, the two most effective medications[4]. That gap is the crisis within the crisis — the distance between people who could be helped and people who actually get help.

The reason to close it is in the data.

These medications do more than ease cravings, they cut the risk of dying:

  • about half — the reduction in all-cause mortality with methadone or buprenorphine, versus no medication[4]
  • roughly 50% — the reduction in mortality with opioid agonist therapy in a separate review[18]
  • 70% — the drop in repeat-overdose risk among survivors who started medication after a heroin or synthetic-opioid overdose[19]

These are not trading one addiction for another. They are the evidence-based standard of care, and people rebuild full lives on them every day. If these figures describe your situation or someone you love, the takeaway is not despair, it is direction: you do not have to face withdrawal alone or guess at the next step.

If any of this lands, the next step doesn’t have to be a big one. Our treatment centers directory can point you to the right level of care. Reaching out today is a real step forward — and one you can make right now.

Frequently asked questions

How many people are affected by oxycodone and opioid addiction?

In 2022, an estimated 9.37 million US adults (about 3.7%) had opioid use disorder, and worldwide roughly 27 million people are affected[4][6]. Oxycodone helped drive that scale: retail sales rose 866% between 1997 and 2007, a surge driven by marketing rather than medical need[1]. Risk is also uneven. In large behavioral studies, the strongest initial pain relief predicted the strongest addiction-like behavior, accounting for about 40% of the variation in compulsive use[7]. Feeling a powerful pull from a first prescription is a risk factor, not a moral failing, and it responds to treatment.

How many people die from oxycodone and other opioids?

Opioid-related deaths rose 806% from 2000 to 2021, and by 2023 nearly 80,000 Americans were dying of opioid-related causes each year; in 2024 opioid use disorder and overdose were tied to 53,774 deaths[5][3][4]. Oxycodone has ranked among the drugs most frequently involved in US overdose deaths from 2017 to 2023[13]. Many of those deaths now involve illicit fentanyl, including counterfeit pills pressed to look exactly like pharmaceutical oxycodone, which kill people who believe they are taking a known dose of a known drug[14]. Most opioid overdoses can be reversed if naloxone (Narcan) is given fast.

Did the 2010 OxyContin reformulation reduce the problem?

It produced a narrow win at a heavy cost. Doctor-shopping for the reformulated brand fell 50% overall and as much as 90% in the highest-risk group, and past-month OxyContin abuse dropped from 45.1% to 26.0% by mid-2012[15][16]. But the demand moved instead of disappearing: heroin abuse exposures rose 42% over the same period, and about 34% of experienced users defeated the tamper-resistant design anyway[2][16]. The lesson researchers drew is that cutting supply alone does not fix addiction.

How did oxycodone lead to heroin and fentanyl?

As reformulation and tighter prescribing squeezed the pill supply, displaced demand flowed into heroin, with heroin exposures jumping 42% right alongside the 2010 reformulation[2]. Heroin markets then expanded and suppliers began cutting and replacing heroin with cheaper, far more potent illicit fentanyl[14]. A person can start with a real prescription, develop dependence, lose access, move to heroin, and then meet fentanyl, with each step more lethal than the one before.

Where is oxycodone use highest in the United States?

Distribution has been strikingly uneven. At the 2010 peak there was a 15-fold difference in oxycodone distribution between the highest- and lowest-prescribing states, and Florida, Delaware, and Tennessee showed consistently elevated levels[5][3]. Where the pills flowed heaviest, opioid harm tended to follow.

Is oxycodone addiction treatable, and do the numbers support it?

Yes, and that is the most important statistic here. In 2022 only 25.1% of people with opioid use disorder received methadone or buprenorphine, the two most effective medications, which is the treatment gap worth closing[4]. The reason to close it is in the data: these medications cut all-cause mortality by roughly half and are tied to about a 70% drop in repeat-overdose risk among survivors[4][18][19]. They are the evidence-based standard of care, not a swap of one addiction for another, and people rebuild full lives on them every day. If the figures here describe you or someone you love, the next step is to reach out for help, not to face withdrawal alone.

Get Treatment Help

If you or someone you love is struggling with addiction, getting help is just a phone call away, or consider trying therapy online with BetterHelp.

Exclusive offer: 20% Off BetterHelp*

Following links to the BetterHelp website may earn us a commission that helps us manage and maintain AddictionHelp.com. *Get 20% off your first month of BetterHelp. Offer valid for new BetterHelp users only. Offer cannot be combined with insurance.

19 Sources
  1. Kibaly, Cherkaouia, Alderete, Jacob A, Liu, Steven H, Nasef, Hazem S, Law, Ping-Yee, Evans, Christopher J, Cahill, Catherine M (2021). Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability. Cellular and molecular neurobiology. https://doi.org/10.1007/s10571-020-01013-y
  2. Coplan, Paul M, Kale, Hrishikesh, Sandstrom, Lauren, Landau, Craig, Chilcoat, Howard D (2013). Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiology and drug safety. https://doi.org/10.1002/pds.3522
  3. Solgama, Jay P, Pradhan, Apoorva, McCall, Kenneth L, Piper, Brian J (2026). Pharmacoepidemiology of Oxycodone in the USA: An Observational Study of ARCOS, Medicaid, and Medicare Drug Databases. Pharmacology research & perspectives. https://doi.org/10.1002/prp2.70210
  4. Harris, Miriam T H, Weinstein, Zoe M, Walley, Alexander Y (2026). Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review. JAMA. https://doi.org/10.1001/jama.2025.26348
  5. Solgama, Jay P, Liu, Edward, Davis, Mellar, Graham, Jove, McCall, Kenneth L, Piper, Brian J (2024). State-level variation in distribution of oxycodone and opioid-related deaths from 2000 to 2021: an ecological study of ARCOS and CDC WONDER data in the USA. BMJ open. https://doi.org/10.1136/bmjopen-2023-073765
  6. Edinoff, Amber N, Sall, Saveen, Honore, Lauryn G, Dies, Ross M, Zaheri, Alexa R, Kataria, Saurabh, Jackson, Eric D, Shekoohi, Sahar, Cornett, Elyse M, Murnane, Kevin S, Kaye, Adam M, Kaye, Alan D (2023). The Use of Oxytocin for the Treatment of Opioid Use Disorder. Current pain and headache reports. https://doi.org/10.1007/s11916-023-01105-6
  7. Kallupi, Marsida, de Guglielmo, Giordano, Carrette, Lieselot L G, Simpson, Sierra, Kononoff, Jenni, Kimbrough, Adam, Smith, Lauren C, Shankar, Kokila, Avelar, Alicia, Conlisk, Dana, Brennan, Molly, Tieu, Lani, Sedighim, Sharona, Boomhower, Brent, Maturin, Lisa, Fannon, McKenzie J, Martinez, Angelica, Crook, Caitlin, Dirik, Selen, Velarde, Nathan, Schweitzer, Paul, Bonnet-Zahedi, Selene, Sneddon, Elizabeth, Plasil, Sonja, Morgan, Alex A, Othman, Dyar N, Sichel, Benjamin, Peng, Beverly, Chitre, Apurva S, Polesskaya, Oksana, Lau, Justin, Vang, Ashley, Solberg Woods, Leah C, Palmer, Abraham A, George, Olivier (2026). Large-scale behavioral characterization of oxycodone self-administration in heterogeneous stock rats reveals initial analgesic effects are associated with addiction-like behaviors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. https://doi.org/10.1038/s41386-026-02348-8
  8. Courchesne-Krak, Natasia S, Chandrasekaran, Anirudh R, Gonzalez, Jean, Bianchi, Sevim B, Tran, Vinh, Johnson, Eric O, Troiani, Vanessa, Hettema, John M, Stein, Murray B, Coon, Hilary, Docherty, Anna R, Berretini, Wade H, MacKillop, James, de Wit, Harriet, Marienfeld, Carla, Palmer, Abraham A, Sanchez-Roige, Sandra (2025). Prescription Opioid Medication Survey: A Tool to Collect Deep Phenotypic Data on the Multifactorial Pathways to Opioid Use Disorder in Clinical and Population-Based Cohorts. Complex psychiatry. https://doi.org/10.1159/000546389
  9. Santo, Thomas, Gisev, Natasa, Campbell, Gabrielle, Colledge-Frisby, Samantha, Wilson, Jack, Tran, Lucy Thi, Lynch, Michelle, Martino-Burke, Daniel, Taylor, Sophia, Degenhardt, Louisa (2024). Prevalence of comorbid substance use disorders among people with opioid use disorder: A systematic review & meta-analysis. The International journal on drug policy. https://doi.org/10.1016/j.drugpo.2024.104434
  10. Santo, Thomas, Campbell, Gabrielle, Gisev, Natasa, Martino-Burke, Daniel, Wilson, Jack, Colledge-Frisby, Samantha, Clark, Brodie, Tran, Lucy Thi, Degenhardt, Louisa (2022). Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. Drug and alcohol dependence. https://doi.org/10.1016/j.drugalcdep.2022.109551
  11. Scicluna, Rhianne L, Kang, James W M, Everett, Nicholas A, Badolato, Connie J, Etchart, Maia G, Kevin, Richard C, Wilson, Bianca B, Boorman, Damien C, Gordon, Rebecca S, Anderson, Lyndsey L, Arnold, Jonathon C, Keay, Kevin A, Bowen, Michael T (2026). Behavioural, pharmacokinetic, and genetic evidence of a cannabidiol-oxycodone drug-drug interaction in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. https://doi.org/10.1016/j.biopha.2026.119277
  12. Barrett, James E, Shekarabi, Aryan, Inan, Saadet (2023). Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments. Pharmacological reviews. https://doi.org/10.1124/pharmrev.121.000506
  13. Garnett, Matthew F, Cisewski, Jodi A, Ahmad, Farida B (2026). Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2017-2023. National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. https://doi.org/10.15620/cdc/174640
  14. Hartmann, Grace E, Sethi, Roopa (2023). The Role of Non-Pharmaceutical Fentanyl-Contaminated Counterfeit Oxycodone in Increasing Opioid Overdoses: A Commentary Review. The primary care companion for CNS disorders. https://doi.org/10.4088/pcc.22nr03433
  15. Chilcoat, Howard D, Coplan, Paul M, Harikrishnan, Venkatesh, Alexander, Louis (2016). Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). Drug and alcohol dependence. https://doi.org/10.1016/j.drugalcdep.2016.06.009
  16. Cicero, Theodore J, Ellis, Matthew S (2015). Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. JAMA psychiatry. https://doi.org/10.1001/jamapsychiatry.2014.3043
  17. Nolan, Michelle L, Harocopos, Alex, Allen, Bennett, Paone, Denise (2020). Reformulation of oxycodone 80 mg to prevent misuse: A cohort study assessing the impact of a supply-side intervention. The International journal on drug policy. https://doi.org/10.1016/j.drugpo.2020.102848
  18. Perry, Danielle, Kirkwood, Jessica Em, Doroshuk, Marissa L, Kelmer, Michael, Korownyk, Christina S, Ton, Joey, Garrison, Scott R (2025). Opioid agonist therapy for opioid use disorder in primary versus specialty care. The Cochrane database of systematic reviews. https://doi.org/10.1002/14651858.cd013672.pub2
  19. Crystal, Stephen, Nowels, Molly, Samples, Hillary, Olfson, Mark, Williams, Arthur Robin, Treitler, Peter (2022). Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients. Drug and alcohol dependence. https://doi.org/10.1016/j.drugalcdep.2022.109269
Written by
Jessica Miller is the Content Manager of Addiction Help

Editorial Director

Jessica Miller is the Editorial Director of Addiction Help. Jessica graduated from the University of South Florida (USF) with an English degree and combines her writing expertise and passion for helping others to deliver reliable information to those impacted by addiction. Informed by her personal journey to recovery and support of loved ones in sobriety, Jessica's empathetic and authentic approach resonates deeply with the Addiction Help community.

Reviewed by
  • Fact-Checked
  • Editor
Kent S. Hoffman, D.O. is a founder of Addiction Help

Co-Founder & Chief Medical Officer

Kent S. Hoffman, D.O. has been an expert in addiction medicine for more than 15 years. In addition to managing a successful family medical practice, Dr. Hoffman is board certified in addiction medicine by the American Osteopathic Academy of Addiction Medicine (AOAAM). Dr. Hoffman has successfully treated hundreds of patients battling addiction. Dr. Hoffman is the Co-Founder and Chief Medical Officer of AddictionHelp.com and ensures the website’s medical content and messaging quality.

Real Help. Real Recovery.

Compare centers, explore options and start your path to recovery today.

Find Treatment Now

"AddictionHelp.com is helping to make recovery available to EVERYONE!"

- Angela N.